

Andrew B Nixon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9082372/publications.pdf>

Version: 2024-02-01

158
papers

5,640
citations

159585

30
h-index

85541

71
g-index

161
all docs

161
docs citations

161
times ranked

9505
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). <i>Angiogenesis</i> , 2022, 25, 47-55.	7.2	8
2	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
3	Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. <i>Oncologist</i> , 2022, 27, 621-e617.	3.7	2
4	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 284-284.	1.6	0
5	Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 413-422.	2.3	2
6	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	5.9	48
7	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN± ± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	7.0	8
8	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	7.0	11
9	Plasma levels of VEGF±± and VCAM±± as predictors of drug±±induced hypertension in patients treated with VEGF±±pathway inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	1
10	A precision medicine approach to stress testing using metabolomics and microribonucleic acids. <i>Personalized Medicine</i> , 2022, 19, 287-297.	1.5	1
11	Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers. <i>Communications Biology</i> , 2022, 5, .	4.4	7
12	Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia. <i>PLoS ONE</i> , 2022, 17, e0268963.	2.5	0
13	Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3553-3553.	1.6	0
14	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	2.9	6
15	Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 325-325.	1.6	2
16	Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).. <i>Journal of Clinical Oncology</i> , 2021, 39, 154-154.	1.6	0
17	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non±±Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3317-3328.	7.0	14
18	Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 465-e917.	3.7	13

#	ARTICLE	IF	CITATIONS
19	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). <i>Oncologist</i> , 2021, 26, 560-e1103.	3.7	6
20	Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3568-3568.	1.6	0
21	Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). <i>Gynecologic Oncology</i> , 2021, 161, 382-388.	1.4	7
22	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. <i>PLoS ONE</i> , 2021, 16, e0252995.	2.5	3
23	Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2500-2508.	2.8	4
24	Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. <i>Current Medical Research and Opinion</i> , 2021, 37, 1769-1778.	1.9	3
25	AdoRN Trial: Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly-diagnosed advanced-stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, S61.	1.4	4
26	Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 372.	2.7	8
27	Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).. <i>Journal of Clinical Oncology</i> , 2021, 39, 343-343.	1.6	0
28	Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.. <i>Journal of Clinical Oncology</i> , 2021, 39, 361-361.	1.6	1
29	Endoglin Targeting: Lessons Learned and Questions That Remain. <i>International Journal of Molecular Sciences</i> , 2021, 22, 147.	4.1	22
30	Proteomic Analysis of Infants Undergoing Cardiopulmonary Bypass Using Contemporary Ontological Tools. <i>Journal of Surgical Research</i> , 2020, 246, 83-92.	1.6	6
31	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. <i>Clinical Cancer Research</i> , 2020, 26, 1288-1296.	7.0	29
32	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	7.1	24
33	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2146-2154.	4.1	18
34	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	7.0	126
35	A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. <i>Cancer</i> , 2020, 126, 3464-3470.	4.1	24
36	Microtransplantation in older patients with <scp>AML</scp>: A pilot study of safety, efficacy and immunologic effects. <i>American Journal of Hematology</i> , 2020, 95, 662-671.	4.1	7

#	ARTICLE	IF	CITATIONS
37	Differential expression of immune related genes in high-grade ovarian serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 662-668.	1.4	3
38	Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3831-3842.	7.0	28
39	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2570-2586.	8.2	134
40	Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1077-1077.	1.6	5
41	Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9065-9065.	1.6	6
42	Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3154-TPS3154.	1.6	3
43	A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with <i>MET</i> amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS270-TPS270.	1.6	2
44	Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with ipilimumab/nivolumab (I+N).. <i>Journal of Clinical Oncology</i> , 2020, 38, 731-731.	1.6	0
45	Phase II study of Dovitinib in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 359-368.	2.9	29
46	A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1032.	2.6	9
47	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1752-1761.	2.3	1
48	A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 909-917.	2.3	13
49	Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 748-752.	1.2	15
50	fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies. <i>BMC Bioinformatics</i> , 2019, 20, 333.	2.6	2
51	A phase I study of gemcitabine+dasatinib (gd) or gemcitabine+dasatinib+cetuximab (GDC) in refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1025-1035.	2.3	6
52	EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione. <i>Toxicological Sciences</i> , 2019, 169, 534-542.	3.1	15
53	Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. <i>Gynecologic Oncology</i> , 2019, 153, 555-561.	1.4	19
54	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.	1.4	35

#	ARTICLE	IF	CITATIONS
55	An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 202-210.	3.7	24
56	Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?. , 2019, 7, 325.		111
57	An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2019, 29, 123-131.	1.5	4
58	RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	17
59	Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3552-3552.	1.6	2
60	Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4005-4005.	1.6	29
61	Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4083-4083.	1.6	3
62	Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15169-e15169.	1.6	43
63	Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.. <i>Journal of Clinical Oncology</i> , 2019, 37, 587-587.	1.6	0
64	On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2019, 37, 588-588.	1.6	0
65	Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3035-3035.	1.6	0
66	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4150-TPS4150.	1.6	1
67	Bevacizumab biosimilars: scientific justification for extrapolation of indications. <i>Future Oncology</i> , 2018, 14, 2507-2520.	2.4	32
68	A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. <i>Oncologist</i> , 2018, 23, 782-790.	3.7	19
69	Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 564.	7.1	19
70	A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients. <i>Annals of Oncology</i> , 2018, 29, viii661-viii662.	1.2	0
71	Genetic variation determines VEGF-A plasma levels in cancer patients. <i>Scientific Reports</i> , 2018, 8, 16332.	3.3	10
72	Cabozantinib in ovarian clear cell cancers: UnMET expectations. <i>Gynecologic Oncology</i> , 2018, 150, 1-2.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2248-2256.	4.1	17
74	A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3555-3555.	1.6	3
75	Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4082-4082.	1.6	6
76	Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3570-3570.	1.6	0
77	Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5507-5507.	1.6	1
78	Developing elite <i>Neurospora crassa</i> strains for cellulosic ethanol production using fungal breeding. <i>Journal of Industrial Microbiology and Biotechnology</i> , 2017, 44, 1137-1144.	3.0	6
79	The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. <i>Neuro-Oncology</i> , 2017, 19, 1217-1227.	1.2	53
80	Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. <i>Radiology</i> , 2017, 285, 311-318.	7.3	14
81	Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC). <i>J Clin Oncol</i> . 2017;35(14):e14001. doi:10.1200/JCO.2017.35.14001	1.6	1
82	Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3528-3528.	1.6	1
83	Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4522-4522.	1.6	1
84	Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11546-11546.	1.6	1
85	TGF- β 2-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. <i>Carcinogenesis</i> , 2016, 37, 1041-1051.	2.8	67
86	Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). <i>Cancer Medicine</i> , 2016, 5, 2249-2260.	2.8	19
87	Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 510-518.	1.6	18
88	Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase IIIa clinical trial. <i>Annals of Oncology</i> , 2016, 27, 1579-1585.	1.2	41
89	Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3597-3597.	1.6	9
90	Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin-paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5521-5521.	1.6	5

#	ARTICLE	IF	CITATIONS
91	MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE). Journal of Urology, 2015, 193, .	0.4	1
92	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine, 2015, 2, 1814-1820.	6.1	13
93	Constancy checks of wellâ€type ionization chambers with externalâ€beam radiation units. Journal of Applied Clinical Medical Physics, 2015, 16, 508-514.	1.9	4
94	Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic. Cancer Journal (Sudbury, Mass), 2015, 21, 322-326.	2.0	11
95	A leave-one-out cross-validation SAS macro for the identification of markers associated with survival. Computers in Biology and Medicine, 2015, 57, 123-129.	7.0	45
96	A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 343-352.	2.3	7
97	Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. Molecular Cancer Therapeutics, 2015, 14, 1048-1056.	4.1	22
98	Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance). Clinical Cancer Research, 2015, 21, 1078-1086.	7.0	67
99	Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. Clinical Cancer Research, 2015, 21, 3442-3452.	7.0	5
100	Phase II trial of dovitinib in recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2050-2050.	1.6	4
101	Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).. Journal of Clinical Oncology, 2015, 33, 306-306.	1.6	0
102	HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).. Journal of Clinical Oncology, 2015, 33, 4543-4543.	1.6	1
103	HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in <i>RAS</i>-wt advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 2015, 33, 3583-3583.	1.6	1
104	Role of TGF-Î² receptor III localization in polarity and breast cancer progression. Molecular Biology of the Cell, 2014, 25, 2291-2304.	2.1	17
105	Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-Î² signaling. Oncogene, 2014, 33, 3970-3979.	5.9	42
106	Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data. Cancer Informatics, 2014, 13s4, CIN.S13634.	1.9	6
107	Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines. Gynecologic Oncology Research and Practice, 2014, 1, 2.	3.6	16
108	Ectodomain shedding of TÎ²RIII is required for TÎ²RIII-mediated suppression of TGF-Î² signaling and breast cancer migration and invasion. Molecular Biology of the Cell, 2014, 25, 2320-2332.	2.1	39

#	ARTICLE	IF	CITATIONS
109	Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 218-225.	2.5	6
110	Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 330-339.	2.6	18
111	Modulation of circulating protein biomarkers following TRC 105 (anti- α Endoglin antibody) treatment in patients with advanced cancer. <i>Cancer Medicine</i> , 2014, 3, 580-591.	2.8	27
112	Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. <i>Investigational New Drugs</i> , 2014, 32, 851-859.	2.6	40
113	The Balance of Cell Surface and Soluble Type III TGF- β 2 Receptor Regulates BMP Signaling in Normal and Cancerous Mammary Epithelial Cells. <i>Neoplasia</i> , 2014, 16, 489-500.	5.3	22
114	The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 349-358.	1.4	25
115	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 700-709.	2.6	4
116	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 241-250.	1.9	25
117	Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. <i>Journal of Clinical Investigation</i> , 2014, 124, 3016-3031.	8.2	28
118	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).. <i>Journal of Clinical Oncology</i> , 2014, 32, 448-448.	1.6	0
119	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11022-11022.	1.6	0
120	Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11020-11020.	1.6	0
121	Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4532-4532.	1.6	1
122	Abstract 2674: Stroma biology identifies heparins as differentiating agents in neuroblastoma. , 2014, , .		0
123	Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. <i>Cancer Medicine</i> , 2013, 2, 234-242.	2.8	64
124	A phase I study of ABT α 510 plus bevacizumab in advanced solid tumors. <i>Cancer Medicine</i> , 2013, 2, 316-324.	2.8	31
125	A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas. <i>Oncologist</i> , 2013, 18, 271-272.	3.7	38
126	Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). <i>Clinical Cancer Research</i> , 2013, 19, 6957-6966.	7.0	95

#	ARTICLE	IF	CITATIONS
127	Dual inhibition of $\alpha_5\beta_1$ integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 237-250.	1.4	15
128	Type III TGF- β 2 receptor downregulation generates an immunotolerant tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2013, 123, 3925-3940.	8.2	94
129	Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4042-4042.	1.6	3
130	Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4520.	1.6	25
131	Abstract 5041: The type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.. , 2013, , .		0
132	Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11036-11036.	1.6	0
133	Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11011-11011.	1.6	0
134	Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 251-258.	2.3	43
135	Modulation of angiogenic biomarkers in patients receiving high-dose TRC105.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21038-e21038.	1.6	0
136	Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13589-e13589.	1.6	0
137	A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. <i>Anticancer Research</i> , 2011, 31, 255-61.	1.1	22
138	Variation in Microenvironmental Effects and Drug Delivery between Different Classes of Antiangiogenic Drugs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S164-S165.	0.8	0
139	Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1798-1808.	4.1	99
140	A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. <i>Anticancer Research</i> , 2010, 30, 1251-6.	1.1	3
141	Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression. <i>Hypertension</i> , 2009, 54, 652-658.	2.7	242
142	The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1115-1124.	4.2	271
143	A Role for Gz in Pancreatic Islet β -Cell Biology. <i>Journal of Biological Chemistry</i> , 2005, 280, 31708-31713.	3.4	44
144	Analysis of the Regulation of Microtubule Dynamics by Interaction of RGSZ1 (RGS20) with the Neuronal Stathmin, SCG10. <i>Methods in Enzymology</i> , 2004, 390, 53-64.	1.0	8

#	ARTICLE	IF	CITATIONS
145	The Interaction of RGSZ1 with SCG10 Attenuates the Ability of SCG10 to Promote Microtubule Disassembly. <i>Journal of Biological Chemistry</i> , 2002, 277, 18127-18133.	3.4	34
146	Regulation of platelet-activating factor synthesis in human neutrophils by MAP kinases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1592, 175-184.	4.1	31
147	HDAC6 is a microtubule-associated deacetylase. <i>Nature</i> , 2002, 417, 455-458.	27.8	2,301
148	Phosphorylation and Nuclear Translocation of a Regulator of G Protein Signaling (RGS10). <i>Journal of Biological Chemistry</i> , 2001, 276, 32828-32834.	3.4	90
149	Acetyl-CoA:1-O-Alkyl-2-lyso-sn-glycero-3-phosphocholine Acetyltransferase Is Directly Activated by p38 Kinase. <i>Journal of Biological Chemistry</i> , 1999, 274, 5469-5473.	3.4	35
150	Differential activation of human neutrophil cytosolic phospholipase A2 and secretory phospholipase A2 during priming by 1,2-diacyl- and 1-O-alkyl-2-acylglycerols. <i>Lipids and Lipid Metabolism</i> , 1998, 1394, 224-234.	2.6	11
151	Comparison of alkylacylglycerol vs. diacylglycerol as activators of mitogen-activated protein kinase and cytosolic phospholipase A2 in human neutrophil priming. <i>Lipids and Lipid Metabolism</i> , 1997, 1347, 219-230.	2.6	13
152	Comparison of acceptor and donor substrates in the CoA-independent transacylate reaction in human neutrophils. <i>Lipids and Lipid Metabolism</i> , 1996, 1300, 187-196.	2.6	8
153	5-Oxo-eicosanoids and Hematopoietic Cytokines Cooperate in Stimulating Neutrophil Function and the Mitogen-activated Protein Kinase Pathway. <i>Journal of Biological Chemistry</i> , 1996, 271, 17821-17828.	3.4	68
154	The Targeting of Leukocytes by 5-Oxo-Eicosanoids. , 1996, , 149-155.		1
155	Activation of 85 kDa PLA2 by Eicosanoids in Human Neutrophils and Eosinophils. <i>Advances in Experimental Medicine and Biology</i> , 1996, 416, 327-331.	1.6	0
156	5-Lipoxygenase Products Modulate the Activity of the 85-kDa Phospholipase A2 in Human Neutrophils. <i>Journal of Biological Chemistry</i> , 1995, 270, 26543-26549.	3.4	69
157	Evaluation of phospholipase C and D activity in stimulated human neutrophils using a phosphono analog of choline phosphoglyceride. <i>Lipids and Lipid Metabolism</i> , 1993, 1169, 25-29.	2.6	8
158	A facile synthesis of 1-O-alkyl-2-(R)-hydroxypropane-3-phosphonocholine (lyso-phosphono-platelet) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	3.2	8